Brief: Polarityte Announces First Subject Enrolled In Phase III Pivotal Study Evaluating Skinte
03/05/2022 14:35
May 3 (Reuters) - PolarityTE Inc PTE.O :
* POLARITYTE ANNOUNCES FIRST SUBJECT ENROLLED IN PHASE III PIVOTAL STUDY
EVALUATING INVESTIGATIONAL NEW DRUG SKINTE® IN DIABETIC FOOT ULCERS
Source text for Eikon: ID:nPn63bRQza
Further company coverage: PTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RegenETP,
See all newsBrief: PolarityTE Receives Delisting Notice From Nasdaq
U.S. STOCKS ON THE MOVE-Biogen, Phoenix Motor, Mastercard
U.S. STOCKS ON THE MOVE-Energy sector, Affirm, Stitch Fix
U.S. STOCKS ON THE MOVE-Shutterstock, Salesforce, Plug Power
Brief: Polarityte And Its Subsidiaries Files Voluntary Petitions For Relief Under Chapter 11